Weight-loss drugs are big business. Novo Nordisk’s blockbuster offering Wegovy is expected to be approved for sale in China this year. That would be another boost for the Danish company. But battered local drugmaker shares have even bigger upside potential.
減肥藥是門大生意。諾和諾德(Novo Nordisk)的重磅產品Wegovy預計將於今年在中國獲批上市。這對這家丹麥公司來說是又一大提振。但是，遭到重創的中國本土製藥商業的股價還有更大的上漲潛力。
您已閱讀10%（355字），剩餘90%（3191字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。